In June I posted that the US Food and Drug Administration (FDA) had controversially approved aducanumab under an ‘accelerated approval process’ for the treatment of Alzheimer’s disease. That post goes into some detail – if interested, you may like to read it. Essentially I understand that this drug has been shown to reduce amyloid deposition in the brain and probably to slow or stop cognitive deterioration but not improve cognitive function. Neurologist Jason Karlawisch, speaking about advice he would give…..